Stellate Ganglion Block to Treat Long COVID 19 Case Series

NCT05812209 | Completed

• 1 other identifier: SGBCOVID
• Study Type: observational
• Target: 41
• Locations: 1 country
• Sites: 1

Brief Summary

An assessment of the effectiveness of Stellate Ganglion Block in alleviating symptoms of Long COVID-19.

Conditions

Long COVID; Long Covid19; Post-COVID-19 Syndrome; Post Acute COVID-19 Syndrome; Dysautonomia; Anosmia; Dysgeusia; Brain Fog; Muscle Pain; Shortness of Breath; Dizziness; Fatigue Post Viral; Cough; Menstrual Cycle Abnormal; Pain

Outcome Measures

Primary Outcomes (1)

• Symptom Response

  Evaluation of the symptoms response to the Stellate Ganglion Block

  3 months

Study Arms (1)

SGB Patients for Long COVID 19

Patients who received ultrasound guided Stellate Ganglion block for symptoms of Long COVID in our Colorado clinics.

Procedure: Stellate Ganglion Block

Interventions

Stellate Ganglion Block PROCEDURE

Ultrasound guided block of the Stellate Ganglion with local anesthetics.

Also known as: SGB

SGB Patients for Long COVID 19

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study included 18 male and 23 females with an age range between 18 and 89 who underwent stellate ganglion block (SGB) for long COVID-19 Syndrome.

You may not qualify if:

• Stellate Ganglion Block Contraindications

Sponsors & Collaborators

• Metamorphosis LTD: lead

Study Sites (1)

Metamorphosis LTD

Cañon City, Colorado, 81212, United States

Location

MeSH Terms

Conditions

Post-Acute COVID-19 Syndrome; Autonomic Nervous System Diseases; Anosmia; Dysgeusia; Mental Fatigue; Myalgia; Dyspnea; Dizziness; Cough; Pain

Condition Hierarchy (Ancestors)

COVID-19; Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases; Post-Infectious Disorders; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Nervous System Diseases; Olfaction Disorders; Sensation Disorders; Neurologic Manifestations; Signs and Symptoms; Taste Disorders; Fatigue; Behavioral Symptoms; Behavior; Muscular Diseases; Musculoskeletal Diseases; Neuromuscular Diseases; Musculoskeletal Pain; Respiration Disorders; Signs and Symptoms, Respiratory

Study Officials

• Lisa Pearson, DNAP

  Metamorphosis LTD

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Dr. Lisa Pearson, CRNA, NSPMc

Study Record Dates

• First Submitted: April 10, 2023
• First Posted: April 13, 2023
• Study Start: September 1, 2022
• Primary Completion: December 31, 2022
• Study Completion: December 31, 2022
• Last Updated: April 13, 2023

Record last verified: 2023-04

Data Sharing

• IPD Sharing: Will share
• Shared Documents: SAP, CSR
• Time Frame: Within a month

Locations

US (1)